Hyderabad :

Suven Life Sciences Ltd, a biopharmaceutical and contract research and manufacturing company, today announced that it has granted an exclusive licence and right to distribute and market its Malathion Lotion USP 0.5% to Taro Pharmaceuticals, North America.

The Hyderabad-based company said it has a US Patent and Abbreviated New Drug Application (ANDA) for it in US, Canada and Mexico.

Taro Pharmaceuticals North America, is a subsidiary of Taro Pharmaceutical Industries Ltd.

Malathion lotion is indicated for patients infected with Pediculus humanus capitis (head lice and their ova) of the scalp hair. In consideration for the exclusive licence and right to distribute and market the lotion Taro will pay Suven a royalty and the arrangement is effective until April 2028 unless otherwise terminated, a company release said without revealing financial details in a press release.

source: http://www.thehindubusinessline.com / Business Line / Home> Companies / The Hindu Bureau / Hyderabad – March 04th, 2014